S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
NASDAQ:RVNC

Revance Therapeutics (RVNC) Stock Price, News & Analysis

$5.37
-0.14 (-2.54%)
(As of 02/21/2024 ET)
Today's Range
$5.32
$5.56
50-Day Range
$5.03
$9.31
52-Week Range
$5.00
$37.98
Volume
960,683 shs
Average Volume
1.45 million shs
Market Capitalization
$471.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.44

Revance Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
243.5% Upside
$18.44 Price Target
Short Interest
Healthy
14.41% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.49mentions of Revance Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.07) to ($2.21) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.15 out of 5 stars

Medical Sector

129th out of 932 stocks

Pharmaceutical Preparations Industry

52nd out of 431 stocks


RVNC stock logo

About Revance Therapeutics Stock (NASDAQ:RVNC)

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

RVNC Stock Price History

RVNC Stock News Headlines

Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Revance to Participate in Upcoming Investor Conferences
Halozyme Therapeutics (HALO) Q4 Earnings Match Estimates
RVNC Revance Therapeutics, Inc.
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Revance Therapeutics Gets Permanent J-Code for Daxxify
Revance Therapeutics Receives Permanent J-Code For DAXXIFY - Quick Facts
What 10 Analyst Ratings Have To Say About Revance Therapeutics
See More Headlines
Receive RVNC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2023
Today
2/22/2024
Next Earnings (Estimated)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RVNC
Employees
534
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.44
High Stock Price Target
$42.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+243.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Net Income
$-356,420,000.00
Net Margins
-193.42%
Pretax Margin
-193.28%

Debt

Sales & Book Value

Annual Sales
$132.57 million
Book Value
$0.15 per share

Miscellaneous

Free Float
83,335,000
Market Cap
$471.54 million
Optionable
Optionable
Beta
0.99
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report














RVNC Stock Analysis - Frequently Asked Questions

Should I buy or sell Revance Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RVNC shares.
View RVNC analyst ratings
or view top-rated stocks.

What is Revance Therapeutics' stock price target for 2024?

8 brokerages have issued 1-year price objectives for Revance Therapeutics' shares. Their RVNC share price targets range from $8.00 to $42.00. On average, they expect the company's stock price to reach $18.44 in the next twelve months. This suggests a possible upside of 243.5% from the stock's current price.
View analysts price targets for RVNC
or view top-rated stocks among Wall Street analysts.

How have RVNC shares performed in 2024?

Revance Therapeutics' stock was trading at $8.79 on January 1st, 2024. Since then, RVNC stock has decreased by 38.9% and is now trading at $5.37.
View the best growth stocks for 2024 here
.

Are investors shorting Revance Therapeutics?

Revance Therapeutics saw a decrease in short interest in the month of January. As of January 31st, there was short interest totaling 12,650,000 shares, a decrease of 14.6% from the January 15th total of 14,810,000 shares. Based on an average daily trading volume, of 1,640,000 shares, the days-to-cover ratio is currently 7.7 days.
View Revance Therapeutics' Short Interest
.

When is Revance Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our RVNC earnings forecast
.

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics, Inc. (NASDAQ:RVNC) announced its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.72) by $0.08. The biopharmaceutical company had revenue of $58.13 million for the quarter, compared to analyst estimates of $58.71 million. Revance Therapeutics had a negative trailing twelve-month return on equity of 903.28% and a negative net margin of 193.42%. The firm's quarterly revenue was up 104.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.88) EPS.

What ETFs hold Revance Therapeutics' stock?

ETFs with the largest weight of Revance Therapeutics (NASDAQ:RVNC) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

What is Mark Foley's approval rating as Revance Therapeutics' CEO?

7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO).

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Capital World Investors (13.60%), Palo Alto Investors LP (5.96%), Vanguard Group Inc. (5.77%), Rubric Capital Management LP (1.66%), CIBC Asset Management Inc (1.31%) and Jennison Associates LLC (1.18%). Insiders that own company stock include Angus C Russell, Aubrey Rankin, Carey Oconnor Kolaja, Dustin S Sjuts, Dwight Moxie, Mark J Foley and Tobin Schilke.
View institutional ownership trends
.

How do I buy shares of Revance Therapeutics?

Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RVNC) was last updated on 2/22/2024 by MarketBeat.com Staff